1. Home
  2. HTD vs WVE Comparison

HTD vs WVE Comparison

Compare HTD & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTD
  • WVE
  • Stock Information
  • Founded
  • HTD 2004
  • WVE 2012
  • Country
  • HTD United States
  • WVE Singapore
  • Employees
  • HTD N/A
  • WVE N/A
  • Industry
  • HTD Finance Companies
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTD Finance
  • WVE Health Care
  • Exchange
  • HTD Nasdaq
  • WVE Nasdaq
  • Market Cap
  • HTD 850.4M
  • WVE 915.6M
  • IPO Year
  • HTD N/A
  • WVE 2015
  • Fundamental
  • Price
  • HTD $24.02
  • WVE $8.56
  • Analyst Decision
  • HTD
  • WVE Strong Buy
  • Analyst Count
  • HTD 0
  • WVE 14
  • Target Price
  • HTD N/A
  • WVE $19.86
  • AVG Volume (30 Days)
  • HTD 92.3K
  • WVE 1.6M
  • Earning Date
  • HTD 01-01-0001
  • WVE 07-30-2025
  • Dividend Yield
  • HTD 8.59%
  • WVE N/A
  • EPS Growth
  • HTD N/A
  • WVE N/A
  • EPS
  • HTD N/A
  • WVE N/A
  • Revenue
  • HTD N/A
  • WVE $104,939,000.00
  • Revenue This Year
  • HTD N/A
  • WVE N/A
  • Revenue Next Year
  • HTD N/A
  • WVE $4.90
  • P/E Ratio
  • HTD N/A
  • WVE N/A
  • Revenue Growth
  • HTD N/A
  • WVE N/A
  • 52 Week Low
  • HTD $16.17
  • WVE $5.04
  • 52 Week High
  • HTD $22.13
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • HTD 58.25
  • WVE 66.89
  • Support Level
  • HTD $23.71
  • WVE $7.69
  • Resistance Level
  • HTD $24.30
  • WVE $8.73
  • Average True Range (ATR)
  • HTD 0.25
  • WVE 0.53
  • MACD
  • HTD -0.01
  • WVE 0.08
  • Stochastic Oscillator
  • HTD 53.52
  • WVE 91.67

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: